Tumor-released galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack

Journal of Biological Chemistry

Volumn 289, Issue 48, 2014, Pages 33311-33319

  Wang, Wei ^a   Guo, Huaijian ^a   Geng, Jianlin ^a   Zheng, Xiaodong ^a   Wei, Haiming ^a,b   Sun, Rui ^a,b   Tian, Zhigang ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EXPERIMENTS; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE; TUMORS;

BINDING PROTEINS; DIRECT INTERACTIONS; DOWN-REGULATION; FC FUSION PROTEINS; IMMUNOPRECIPITATES; NATURAL KILLER CELLS; NON-OBESE DIABETICS; THERAPEUTIC TARGETS;

CYTOLOGY;

GALECTIN 3; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D; GALECTIN-3, HUMAN; HYBRID PROTEIN; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; NCR3 PROTEIN, HUMAN; TUMOR PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURFACE; COCULTURE; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; EMBRYO; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR CELL; TUMOR ESCAPE; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA; ANIMAL; CANCER TRANSPLANTATION; CELLULAR IMMUNITY; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; HUMAN; IMMUNOLOGY; NEOPLASM; NONOBESE DIABETIC MOUSE; SCID MOUSE; XENOGRAFT;

ANIMALS; DOWN-REGULATION; GALECTIN 3; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HETEROGRAFTS; HUMANS; IMMUNITY, CELLULAR; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MICE; MICE, INBRED NOD; MICE, SCID; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECOMBINANT FUSION PROTEINS; TUMOR ESCAPE;

EID: 84912128135     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.603464     Document Type: Article

References (41)

1. Liu, F. T., and Rabinovich, G. A. (2005) Galectins as modulators of tumour progression. Nat. Rev. Cancer 5, 29-41
2. Sturm, A., Lensch, M., André, S., Kaltner, H., Wiedenmann, B., Rosewicz, S., Dignass, A. U., and Gabius, H. J. (2004) Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J. Immunol. 173, 3825-3837
3. Lahm, H., André, S., Hoeflich, A., Fischer, J. R., Sordat, B., Kaltner, H., Wolf, E., and Gabius, H. J. (2001) Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J. Cancer Res. Clin. Oncol. 127, 375-386
4. Lotan, R., Matsushita, Y., Ohannesian, D., Carralero, D., Ota, D. M., Cleary, K. R., Nicolson, G. L., and Irimura, T. (1991) Lactose-binding lectin expression in human colorectal carcinomas: relation to tumor progression. Carbohydr. Res. 213, 47-57
5. Miyazaki, J., Hokari, R., Kato, S., Tsuzuki, Y., Kawaguchi, A., Nagao, S., Itoh, K., and Miura, S. (2002) Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol. Rep. 9, 1307-1312
6. Moutsatsos, I. K., Wade, M., Schindler, M., and Wang, J. L. (1987) Endogenous lectins from cultured cells: nuclear localization of carbohydrate-binding protein 35 in proliferating 3T3 fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 84, 6452-6456
7. Perillo, N. L., Marcus, M. E., and Baum, L. G. (1998) Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J. Mol. Med. 76, 402-412
8. Sato, S., and Hughes, R. C. (1994) Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages. J. Biol. Chem. 269, 4424-4430
9. Honjo, Y., Nangia-Makker, P., Inohara, H., and Raz, A. (2001) Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin. Cancer Res. 7, 661-668
10. Moon, B. K., Lee, Y. J., Battle, P., Jessup, J. M., Raz, A., and Kim, H. R. (2001) Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am. J. Pathol. 159, 1055-1060
11. Peng, W., Wang, H. Y., Miyahara, Y., Peng, G., and Wang, R. F. (2008) Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res. 68, 7228-7236
12. Ochieng, J., Warfield, P., Green-Jarvis, B., and Fentie, I. (1999) Galectin-3 regulates the adhesive interaction between breast carcinoma cells and elastin. J. Cell. Biochem. 75, 505-514
13. Le Marer, N., and Hughes, R. C. (1996) Effects of the carbohydrate-binding protein galectin-3 on the invasiveness of human breast carcinoma cells. J. Cell. Physiol. 168, 51-58
14. Thijssen, V. L., Poirier, F., Baum, L. G., and Griffioen, A. W. (2007) Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood 110, 2819-2827
15. Fukumori, T., Takenaka, Y., Yoshii, T., Kim, H. R., Hogan, V., Inohara, H., Kagawa, S., and Raz, A. (2003) CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res. 63, 8302-8311
16. Müller, S., Schaffer, T., Flogerzi, B., Fleetwood, A., Weimann, R., Schoepfer, A. M., and Seibold, F. (2006) Galectin-3 modulates T cell activity and is reduced in the inflamed intestinal epithelium in IBD. Inflamm. Bowel Dis. 12, 588-597
17. Demotte, N., Wieërs, G., Van Der Smissen, P., Moser, M., Schmidt, C., Thielemans, K., Squifflet, J. L., Weynand, B., Carrasco, J., Lurquin, C., Courtoy, P. J., and van der Bruggen, P. (2010) A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res. 70, 7476-7488
18. Guha, P., Kaptan, E., Bandyopadhyaya, G., Kaczanowska, S., Davila, E., Thompson, K., Martin, S. S., Kalvakolanu, D. V., Vasta, G. R., and Ahmed, H. (2013) Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis. Proc. Natl. Acad. Sci. U.S.A. 110, 5052-5057
19. Spits, H., Blom, B., Jaleco, A. C., Weijer, K., Verschuren, M. C., van Dongen, J. J., Heemskerk, M. H., and Res, P. C. (1998) Early stages in the development of human T, natural killer and thymic dendritic cells. Immunol. Rev. 165, 75-86
20. Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., and Moretta, L. (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19, 197-223
21. Cantoni, C., Bottino, C., Vitale, M., Pessino, A., Augugliaro, R., Malaspina, A., Parolini, S., Moretta, L., Moretta, A., and Biassoni, R. (1999) NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J. Exp. Med. 189, 787-796
22. Vitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R., Moretta, L., and Moretta, A. (1998) NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187, 2065-2072
23. Pessino, A., Sivori, S., Bottino, C., Malaspina, A., Morelli, L., Moretta, L., Biassoni, R., and Moretta, A. (1998) Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J. Exp. Med. 188, 953-960
24. Nalabolu, S. R., Shukla, H., Nallur, G., Parimoo, S., and Weissman, S. M. (1996) Genes in a 220-kb region spanning the TNF cluster in human MHC. Genomics 31, 215-222
25. Pende, D., Parolini, S., Pessino, A., Sivori, S., Augugliaro, R., Morelli, L., Marcenaro, E., Accame, L., Malaspina, A., Biassoni, R., Bottino, C., Moretta, L., and Moretta, A. (1999) Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 190, 1505-1516
26. Bottino, C., Castriconi, R., Moretta, L., and Moretta, A. (2005) Cellular ligands of activating NK receptors. Trends Immunol. 26, 221-226
27. Lanier, L. L. (2005) NK cell recognition. Annu. Rev. Immunol. 23, 225-274
28. Tsuboi, S., Sutoh, M., Hatakeyama, S., Hiraoka, N., Habuchi, T., Horikawa, Y., Hashimoto, Y., Yoneyama, T., Mori, K., Koie, T., Nakamura, T., Saitoh, H., Yamaya, K., Funyu, T., Fukuda, M., and Ohyama, C. (2011) A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J. 30, 3173-3185
29. Suzuki, Y., Sutoh, M., Hatakeyama, S., Mori, K., Yamamoto, H., Koie, T., Saitoh, H., Yamaya, K., Funyu, T., Habuchi, T., Arai, Y., Fukuda, M., Ohyama, C., and Tsuboi, S. (2012) MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis. Int. J. Oncol. 40, 1831-1838
30. Zheng, X., Wang, Y., Wei, H., Sun, R., and Tian, Z. (2009) LFA-1 and CD2 synergize for the Erk1/2 activation in the natural killer (NK) cell immunological synapse. J. Biol. Chem. 284, 21280-21287
31. Dupont, W. D., and Plummer, W. D., Jr. (1990) Power and sample size calculations: a review and computer program. Control. Clin. Trials 11, 116-128
32. Sun, H., Sun, C., Tian, Z., and Xiao, W. (2013)NKcells in immunotolerant organs. Cell Mol. Immunol. 10, 202-212
33. Cheng, M., Chen, Y., Xiao, W., Sun, R., and Tian, Z. (2013) NK cell-based immunotherapy for malignant diseases. Cell Mol. Immunol. 10, 230-252
34. Ruebel, K. H., Jin, L., Qian, X., Scheithauer, B. W., Kovacs, K., Nakamura, N., Zhang, H., Raz, A., and Lloyd, R. V. (2005) Effects of DNA methylation on galectin-3 expression in pituitary tumors. Cancer Res. 65, 1136-1140
35. Iurisci, I., Tinari, N., Natoli, C., Angelucci, D., Cianchetti, E., and Iacobelli, S. (2000) Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin. Cancer Res. 6, 1389-1393
36. Vereecken, P., Zouaoui Boudjeltia, K., Debray, C., Awada, A., Legssyer, I., Sales, F., Petein, M., Vanhaeverbeek, M., Ghanem, G., and Heenen, M. (2006) High serum galectin-3 in advanced melanoma: preliminary results. Clin. Exp. Dermatol. 31, 105-109
37. Zubieta, M. R., Furman, D., Barrio, M., Bravo, A. I., Domenichini, E., and Mordoh, J. (2006) Galectin-3 expression correlates with apoptosis of tumor- associated lymphocytes in human melanoma biopsies. Am. J. Pathol. 168, 1666-1675
38. Friese, M. A., Platten, M., Lutz, S. Z., Naumann, U., Aulwurm, S., Bischof, F., Bühring, H. J., Dichgans, J., Rammensee, H. G., Steinle, A., and Weller, M. (2003) MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res. 63, 8996-9006
39. Pogge von Strandmann, E., Simhadri, V. R., von Tresckow, B., Sasse, S., Reiners, K. S., Hansen, H. P., Rothe, A., Böll, B., Simhadri, V. L., Borchmann, P., McKinnon, P. J., Hallek, M., and Engert, A. (2007) Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27, 965-974
40. Brandt, C. S., Baratin, M., Yi, E. C., Kennedy, J., Gao, Z., Fox, B., Haldeman, B., Ostrander, C. D., Kaifu, T., Chabannon, C., Moretta, A., West, R., Xu, W., Vivier, E., and Levin, S. D. (2009) The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206, 1495-1503
41. Radosavljevic, G., Jovanovic, I., Majstorovic, I., Mitrovic, M., Lisnic, V. J., Arsenijevic, N., Jonjic, S., and Lukic, M. L. (2011) Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity. Clin. Exp. Metastasis 28, 451-462